Pfizer's Lung Cancer Drug Candidate Falls Short Overall, Shows Benefit In Select Patients

기사 요약

Pfizer's sigvotatug vedotin missed its Phase 3 OS goal in NSCLC but showed encouraging results in second-line patients.